口腔癌患者に対するテーラーメイド型ペプチドワクチン療法についての基礎的研究

口腔癌患者定制肽疫苗治疗的基础研究

• 批准号: 17791504
• 负责人: 矢毛石 玲
• 金额: $ 1.22万
• 依托单位: Kurume University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Young Scientists (B)
• 财政年份: 2005
• 资助国家: 日本
• 起止时间: 2005 至 2006
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-17791504/
• 关键词: 癌; 免疫学

久留米大学で同定された癌抗原ペプチドのなかで,P56lckおよびSART-3癌抗原ペプチドが,口腔扁平上皮癌患者に対する特異的癌ワクチン療法の標的分子になりえる可能性があるかを検討した.対象は久留米大学医学部歯科口腔医療センターで加療した口腔扁平上皮癌一次症例である.まずP56lck抗原の発現を免疫組織化学的に検討したところ,13/27(48%)の陽性率を示した.また,RT-PCRでは口腔扁平上皮癌細胞株,癌切除組織において発現が確認された.一方,Western blotting法を用いて,SART-3抗原の発現を核分画および細胞質分画でそれぞれ検討したところ,細胞株ではいずれも100%の発現を示した.切除癌組織では,核分画が19/31(61%),細胞質分画では,12/31(39%)の発現率であった.さらにP56lckおよびSART-3ペプチドがHLA-24拘束性にCTLを誘導するのかを,ELISA法を用いたIFN-γ産生量の測定にて検討したところ,いずれもペプチド特異的にCTLを誘導することができた.以上の結果に日本人の約6割がHLA-A24を有していることを加味すると,P56lck, SART-3分子が,日本人の口腔扁平上皮癌患者に対する,テーラーメイド型ペプチドワクチン療法の標的分子候補になりうる可能性が示唆された.今後,日本人の約4割が有していると言われる,HLA-A2に関しても,解析を進めていきたい.

In Jiulumi University, we have the same determination of cancer antigen, SART-3 cancer antigen, P56lck cancer antigen, oral squamous cell carcinoma, oral squamous cell carcinoma. For example, in the Department of Stomatology, Department of Medicine, Jiulumi University, one case of oral flat epithelial carcinoma was diagnosed. The expression of P56lck antigen was detected by immunocytochemistry, and the sex rate was 27% (48%). Oral squamous cell carcinoma cell line was examined by RT-PCR, and the tumor tissue was confirmed by histological examination. On the other hand, the Western blotting method was used to detect the nuclear fraction of the SART-3 antigen, the cell line and the cell line. After resection of the cancer tissue, the nuclear fraction was 19% 31 (61%), the cell size was 31% (39%), and the incidence rate was 31% (39%). This is the first time that the HLA-24 binding CTL has been detected by the P56lck method. The ELISA method uses the IFN- γ generation method to determine the size of the device, and the CTL guide of the special device. The above results showed that the molecular phenotype of HLA-A24 in Japanese patients with oral flat epithelial carcinoma was significantly higher than that in Japanese patients with oral squamous cell carcinoma, and the molecular phenotype of oral squamous cell carcinoma was significantly higher than that in patients with oral squamous cell carcinoma. From now on, about 4 percent of the Japanese people will have to talk about it, HLA-A2 will talk about it, and analyze how they will make progress.